Lung Cancer

Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.

Alectinib exhibited a CNS DFS improvement, with a 63% reduction in the risk of this event, and 4-year CNS DFS rate was 90.4% vs 76.1% with chemotherapy.

Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E–mutated non–small cell lung cancer.

Data from the KEYNOTE-671 trial support the use of pembrolizumab among patients with non–small cell lung cancer in the perioperative setting.

Data from the phase 3 HARMONi-6 study may support ivonescimab plus chemotherapy as a new standard of care in advanced squamous non–small cell lung cancer.

Slow accrual led to the early stopping of the phase 3 DREAM3R trial assessing durvalumab/chemotherapy in advanced pleural mesothelioma.

OptiTROP-Lung04 data show sacituzumab tirumotecan cut the risk of progression or death by 51% in patients with nonsquamous EGFR-mutated NSCLC resistant to EGFR TKIs.

Osimertinib plus chemotherapy significantly improved overall survival in EGFR-mutated NSCLC, outperforming monotherapy across various prognostic factors.

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Alectinib shows promising long-term survival benefits over crizotinib for advanced ALK-positive NSCLC, highlighting significant clinical advancements.

Sevabertinib monotherapy was deemed tolerable across various cohorts of patients who were pretreated and treatment-naïve with HER2-mutant advanced NSCLC.

Results from the Beamion LUNG-1 study showed that first-line zongertinib yielded continued benefit for patients with HER2-mutated NSCLC.

The safety profile of durvalumab after radiotherapy was consistent with durvalumab after chemoradiotherapy among those with unresectable stage III NSCLC.

Trials slated for presentation at the 2025 ESMO Congress may reveal practice-changing data across different breast and lung cancer populations.

Developers plan to discuss a regulatory path to conditional marketing authorization for OST-HER2 in the UK, US, and EU in resected metastatic osteosarcoma.

Treatment-related AEs with sunvozertinib were consistent with EGFR tyrosine kinase inhibitors in patients with NSCLC with EGFR exon 20 insertion mutations.

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

Phase 2b findings demonstrate improved 2-year survival outcomes with OST-HER2 compared with historical control data.

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.

A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

Use of PET-guided radiotherapy may enable the opportunity to incorporate biological information into the planning and delivery of radiation.

Experts discuss shifting preferences in EGFR-mutated NSCLC treatments, highlighting new survival data from the FLAURA2 and MARIPOSA trials shared at ELCC 2025.

Experts discuss innovative treatments for extensive-stage small cell lung cancer, highlighting tarlatamab's potential and management of adverse effects.

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.